Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-251-0005
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$387.29 million
Profitability
Miscellaneous
Employees804
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) posted its quarterly earnings data on Thursday, August, 8th. The medical equipment provider reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.02. The medical equipment provider earned $93.60 million during the quarter, compared to the consensus estimate of $88.40 million. Nevro had a negative net margin of 24.51% and a negative return on equity of 41.07%. The firm's revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.35) earnings per share. View Nevro's Earnings History.
When is Nevro's next earnings date?
What guidance has Nevro issued on next quarter's earnings?
Nevro updated its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $368-374 million, compared to the consensus revenue estimate of $366.97 million.
What price target have analysts set for NVRO?
11 brokers have issued 1 year target prices for Nevro's stock. Their forecasts range from $35.00 to $98.00. On average, they expect Nevro's share price to reach $65.7273 in the next year. This suggests that the stock has a possible downside of 26.3%. View Analyst Price Targets for Nevro.
What is the consensus analysts' recommendation for Nevro?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nevro.
What are Wall Street analysts saying about Nevro stock?
Here are some recent quotes from research analysts about Nevro stock:
- 1. According to Zacks Investment Research, "Nevro exited the second quarter on a weak note. The company’s domestic and international revenues deteriorated year over year. Loss per share widened on a year-over-year basis. Significant contraction in gross margin raises concern. Surge in operating expenses adds to the woes. The stock is overvalued at the moment. On the bright side, increased R&D expenses reflect focus on innovation. The guidance for 2019 is also promising. Management is further optimistic about the long-term prospects of the flagship Senza II platform, launched late last year. Nevro is also on track to launch its next product platform, Omnia, which is expected to lend the company a competitive edge in the near future. The stock has outperformed the industry over the past year." (8/13/2019)
- 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019)
Has Nevro been receiving favorable news coverage?
Media coverage about NVRO stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nevro earned a news impact score of 0.9 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Nevro.
Are investors shorting Nevro?
Nevro saw a decrease in short interest in August. As of August 15th, there was short interest totalling 3,780,800 shares, a decrease of 10.2% from the July 15th total of 4,210,000 shares. Based on an average daily volume of 415,600 shares, the short-interest ratio is currently 9.1 days. Currently, 13.0% of the shares of the stock are sold short. View Nevro's Current Options Chain.
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include ABIOMED (ABMD), Insulet (PODD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Glaukos (GKOS), Irhythm Technologies (IRTC) and Cardiovascular Systems (CSII).
What other stocks do shareholders of Nevro own?
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
- Mr. Patrick Schmitz, VP of Operations (Age 59)
- Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
- Mr. Doug Alleavitch, VP of Quality (Age 58)
- Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)
Who are Nevro's major shareholders?
Nevro's stock is owned by many different of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.97%), Vanguard Group Inc. (8.75%), BlackRock Inc. (8.36%), D. E. Shaw & Co. Inc. (6.69%), Invesco Ltd. (6.46%) and Perceptive Advisors LLC (3.68%). Company insiders that own Nevro stock include Andrew H Galligan, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which major investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Tamarack Advisers LP, Birch Run Capital Advisors LP, Canada Pension Plan Investment Board, Point72 Asset Management L.P., Renaissance Technologies LLC, Gabelli Funds LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Nevro.
Which major investors are buying Nevro stock?
NVRO stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Price T Rowe Associates Inc. MD, Perceptive Advisors LLC, Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Rock Springs Capital Management LP, Vanguard Group Inc. and Russell Investments Group Ltd.. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $89.20.
How big of a company is Nevro?
Nevro has a market capitalization of $2.75 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.
What is Nevro's official website?
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NYSE NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
